Floatz logo

Nivolumab

ALK Genomic Tumor Aberrations

7 Hills Pharma, LLCmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the ALK Genomic Tumor Aberrations cohort.

Asset / SponsorPhaseRating
Alintegimod
7 Hills Pharma, LLC
Phase 1/2CCC
Ipilimumab
7 Hills Pharma, LLC
Phase 1/2CCC

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →